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The real impact of chemotherapy on the survival time of patients with advanced gastrointestinal tumours has still to be established. Recently, some chemotherapeutic regimens, such as cisplatin, 5-fluorouracil and epirubicin (Cunningham et al., 1991) , have been proven to be particularly effective in gastric cancer. However, the important side-effects related to the aggressive chemotherapies constitute detrimental factors for the quality of life. These considerations justify the elaboration of new therapeutic strategies of digestive tract tumours, including endocrine and immune approaches. The immunotherapy with interleukin-2 (IL-2) would represent one of the most promising biological strategies, capable of activating the antitumour immune response (Grimm et al., 1982) . At present, however, renal cell carcinoma and melanoma seem to be the only neoplasms which have been reported to respond to IL-2 immunotherapy (Rosenberg et al., 1987) , while most solid tumour histotypes have been shown to be less responsive to IL-2. Several cytokines have been used in association to enhance IL-2 efficacy, without, however, any clear increase in IL-2 antitumour activity. The recent investigations of the interactions between neuroendocrine and immune systems (Mathews et al., 1983; McCann et al., 1987) have shown that several neurohormones may modulate the immune responses, including IL-2-mediated antitumour cytotoxicity. Within the neuroendocrine system, the indole melatonin (MLT), which is released by the pineal gland, has appeared to play an important immunomodulating role, either in animals (Maestroni et al., 1986) or in humans (Lissoni et al., 1989) . Therefore, another therapeutic approach to enhance IL-2 antitumour activity could be represented by the concomitant administration of immunostimulating neurohormones, such as MLT. Our preliminary clinical studies have shown that MLT may improve the immune status of metastatic cancer patients (Lissoni et al., 1989) and to enhance the biological activity of IL-2 (Lissoni et al., 1991) with a following decrease in the dose of IL-2 required to activate host biological response. Moreover, our previous clinical trials have demonstrated that the association between IL-2 and MLT may induce tumour regressions in advanced non-small cell lung cancer, which is generally nonresponsive to IL-2 alone (Rosenberg et al., 1987) . On the basis of these considerations, we have designed a clinical study to evaluate the efficacy and the tolerability of the association between IL-2 and MLT in patients with advanced tumours of the digestive tract, which are generally less responsive to IL-2 alone (Dillman et al., 1991 MLT was supplied by Medea Research (Milan, Italy). Human recombinant IL-2 was supplied by Euro-Cetus (Amsterdam, Holland). MLT was given orally at a dose of 50mg/day in the evening (8.00 p.m.) because of its greater biological activity in the night (Bartsch & Bartsch, 1981) . MLT was given every day, starting 7 days before the first IL-2 injection as an induction phase to enhance host biological response to IL-2 (Lissoni et al., 1991) . IL-2 was injected subcutaneously at 3 million IU/day at 8.00 p.m. for 6 days/week for 4 consecutive weeks, corresponding to one cycle of therapy. We decided to administer IL-2 subcutaneously because of its lower toxicity in comparison to the intravenous route of administration (Atzpodien et al., 1991) . Moreover, we decided to give IL-2 in the evening because of the spontaneous increase in lymphocyte proliferative capacity in this period of the day (Ritchie et al., 1983) . In nonprogressed patients, a second cycle was given after a rest period of 3 weeks, after that patients followed a maintenance period consisting of 1 week of therapy every month until Table II . All tumour regressions were documented by CT scan. Toxicity was low in all patients, and in particular no cardiovascular, pulmonary, renal or haematological complications occurred. Fever higher than 38°C was observed in only 6/35 (17%) patients, but it was limited to the first day of IL-2 injection, which was made during the admission at the hospital, after that patients followed IL-2 administration as a home therapy. The only other side-effect was anorexia, which occurred in 3/35 (8%) patients. On the contrary, a clear improvement in the performance status was obtained in 9/35 (26%) patients.
Lymphocyte and eosinophil mean increase, as evaluated on the first immunotherapeutic cycle, was significantly higher in patients who responded or had a s.d. than in those progressing under treatment as shown in Table III . On the contrary, mean increase in serum levels of neopterin was significantly higher in progressed patients than in those with response or s.d. (6.8 ± 0.7 vs 2.6 ± 0.3 ng ml-'; mean + s.e., P < 0.01). (Lissoni et al., 1992) . The mechanisms by which MLT could synergise with IL-2 have still to be better defined; however, they include at least in part the modulation of suppresive events occurring during the immunotherapy (Lissoni et al., 1991) . In any case, randomised clinical trials with IL-2 vs IL-2 plus MLT will be required to define the real role of MLT as a possible agent to extent the spectrum of IL-2 anti-tumour efficacy in humans.
As far as the relation between biological effects and clinical response is concerned, this study would suggest that the inhibitory control of tumour growth, obtained with IL-2 plus MLT, is mediated by lymphocytes and eosinophils, whereas the activation of macrophages, as documented by neopterin increase, would negatively influence the efficacy of the immunotherapy. This consideration is supported by the evidence of a greater increase in lymphocyte and eosinophil number and of a lower rise in neopterin levels in patients with response or s.d. than in the progressed ones. The importance of host biological response in mediating the efficacy of the immunotherapy is also suggested by the lower response rate in patients previously treated with chemotherapy than in the untreated ones. This finding could depend on chemotherapy-induced damage of bone marrow, which is the main source of cytotoxic anticancer cells. Therefore, an eventual immunotherapeutic treatment with IL-2 and MLT would have to precede the chemotherapy in future possible chemoimmunotherapeutic combinations of advanced neoplasms of the digestive tract.
In conclusion, this study shows that the immunotherapy with low-dose IL-2 and the pineal hormone MLT may represent a new effective and well tolerated therapy of advanced tumours of the digestive tract, apparently mainly in gastric cancer and hepatocarcinoma.
